This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Third View: Discussing BridgeBio's Pharma Inc.'s recent FDA approval results for Attruby, a TTR stabilizer which reduces cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients.
Ticker(s): BBIOWho's the expert?
Institution: National Jewish Health
- Director of clinical cardiology at National Jewish Health, associate professor of clinical practice and the university of Colorado, and fellow of the American college of cardiology.
- Currently manages ~2000 patients with high LDL-C.
- Research interests include cardiac sarcoid, public health, exercise and health outcomes, and cardiac nutrition.
Interview GoalThis conversation will focus on the current treatment landscape and potential use of Attruby for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
